Biblio Discovery — Demo Discovery Service

4 results for "Philippe Merle"

Showing 1–4 · 0.43 seconds · RSS

  1. Journal Article Full text

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

    Ann‐Lii Cheng; Shukui Qin; Masafumi Ikeda et al.

    Journal of Hepatology · 2021 · English · OpenAlex Scopus

    BACKGROUND & AIMS: IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of…

  2. Journal Article Full text

    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S. Finn; Shukui Qin; Masafumi Ikeda et al.

    New England Journal of Medicine · 2020 · English · OpenAlex Scopus

    BACKGROUND: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who…

  3. Journal Article Full text

    Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

    Robin Kate Kelley; Lorenza Rimassa; Ann‐Lii Cheng et al.

    The Lancet Oncology · 2022 · English · OpenAlex Scopus

    BACKGROUND: Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. METHODS: COSMIC-312 is an…